Nebenwirkungen · Forxiga
Forxiga 5 mg film-coated tablets Forxiga 10 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 13
HOS-125397 · Präparat HOS-096051
In the DAPA-HF and DELIVER studies, eGFR decreased over time in both the dapagliflozin group and the placebo group. In DAPA-HF, the initial decrease in mean eGFR was -4.3 mL/min/1.73 m2 in the dapagliflozin group and -1.1 mL/min/1.73 m2 in the placebo group. At 20 months, change from baseline in eGFR was similar between the treatment groups: -5.3 mL/min/1.73 m2 for dapagliflozin and -4.5 mL/min/1.73 m2 for placebo. In DELIVER, the decrease in mean eGFR at one month was -3.7 mL/min/1.73 m2 in the dapagliflozin group and -0.4 mL/min/1.73 m2 in the placebo group. At 24 months, change from baseline in eGFR was similar between treatment groups: -4.2 mL/min/1.73 m2 in the dapagliflozin group and -3.2 mL/min/1.73 m2 in the placebo group.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-12T16:11:00Z · SHA-256 a32f3f48ad3ffeffd85467179c7cd7d2f4f8e65c471ebf5e9fcd92a61c71299a · Passage 112cfdd2d179203493c2671f6759880027c8cb076888c4132cab26aae4ec5660 · Zeichen 20573–21313 im Abschnitt